Article
Mitochondrial structure and function adaptation in residual triple negative breast cancer cells surviving chemotherapy treatment
2022-02-25
Abstract excerpt
<h4>ABSTRACT</h4> Neoadjuvant chemotherapy (NACT) used for triple negative breast cancer (TNBC) eradicates tumors in approximately 45% of patients. Unfortunately, TNBC patients with substantial residual cancer burden have poor metastasis free and overall survival rates. We previously demonstrated mitochondrial oxidative phosphorylation (OXPHOS) was elevated and was a unique therapeutic dependency of residual TNBC...
Topics
Open a Topic to create a Post that cites this publication.
Identifiers and source
- Literature Corpus work
- 93f36d0b-5142-5b6a-b3d2-841ea13bc927
- DOI
- 10.1101/2022.02.25.481996
